Is Bausch Health Companies Inc (BHC) overvalued? · rev $9.63B
Bausch Health Companies Inc (BHC) is a drug manufacturers - specialty & generic company listed on NYSE.
This page asks whether Bausch Health Companies Inc (BHC) looks expensive on cached numbers — not a short thesis.
Latest reported BHC revenue for 2024-12-31 was $9.63B. Net income was -$72.0M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. BHC currently screens at market cap $1.78B.
BHC currently screens at market cap $1.78B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BHC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BHC stock page for the full model, not this heading.
Not investment advice.